Currency In USD
| Previous Close | 47.87 |
| Open | 48.73 |
| Day High | 51.69 |
| Day Low | 46.24 |
| 52-Week High | 93.61 |
| 52-Week Low | 22.31 |
| Volume | 2.85M |
| Average Volume | 3.52M |
| Market Cap | 4.6B |
| PE | 37.52 |
| EPS | 1.37 |
| Moving Average 50 Days | 49.99 |
| Moving Average 200 Days | 54.45 |
| Change | 3.53 |
Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
MORRISVILLE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that it will report its full
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress
GlobeNewswire Inc.
Jan 27, 2026 1:30 PM GMT
MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present thr
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
GlobeNewswire Inc.
Jan 09, 2026 11:30 AM GMT
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive